Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
VariZIG Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The expansion observed in the past period was driven by the access to plasma fractionation methods, a growing understanding of complications arising from varicella, the broadening of prophylaxis guidelines within hospitals, official endorsements for hyperimmune globulin products, and a well-developed vaccination framework.
The anticipated expansion during the forecast period is driven by heightened requirements for safeguarding immunocompromised individuals, a stronger emphasis on both maternal and neonatal healthcare, broader development of plasma collection infrastructures, progressive improvements in biologic safety screening protocols, and increased funding directed toward preventive immunotherapeutic approaches. Key developments shaping this forecast period encompass a greater adoption of passive immunization treatments, an elevated priority on protecting high-risk patient populations, the enlargement of biological products derived from plasma, a growing focus on post-exposure preventive measures, and refined procedures for managing cold-chain logistics.
Download A Free Sample Report For Comprehensive Market Insights:
VariZIG Market Growth Drivers And Industry Catalysts
The growing frequency of varicella-zoster virus infections is anticipated to propel the varizig market forward. Varicella-zoster virus (VZV) is a highly transmissible pathogen responsible for chickenpox as an initial infection, with the potential to reemerge later in life as shingles (herpes zoster). This increase in VZV infections, which result in conditions like chickenpox and shingles, is driven by factors such as lower vaccination coverage, an aging demographic, and immunosuppression arising from medical therapies. Varizig offers passive immunity to VZV patients, lessening the intensity and length of chickenpox symptoms, preventing complications in vulnerable groups like immunocompromised individuals, and shielding neonates and pregnant women exposed to the virus from severe outcomes. As an example, in November 2024, the Florida Department of Health, a US government agency, reported that varicella cases rose to 653 in 2023, compared to 428 in 2022. Consequently, the escalating incidence of varicella-zoster virus infections is fueling the varizig market.
The expansion of healthcare spending is expected to drive the varizig market ahead. Healthcare spending encompasses all expenditures on health services and products, covering medical care, hospital services, preventive measures, medications, research, infrastructure, and administrative costs aimed at preserving or enhancing individual and population health. This spending is influenced by an aging population, technological advancements in medicine, a growing prevalence of chronic diseases, and heightened demand for healthcare services. Such expenditure supports varizig by providing funds to acquire and distribute this critical immune globulin, ensuring its accessibility for at-risk groups, enabling healthcare professionals to deliver prompt treatment for VZV infections, and alleviating the overall healthcare burden from severe virus-related complications. For instance, in May 2024, the Office for National Statistics, a UK government department, noted that UK healthcare spending rose by 5.6% between 2022 and 2023, following a 0.9% increase in 2022, reaching approximately $317.63 billion (£292 billion) in 2023. Thus, rising healthcare spending is propelling the varizig market’s growth.
VariZIG Market Segment Analysis And Revenue Opportunities
The varizig market covered in this report is segmented –
1) By Patient Condition: Immunocompromised Patients, Pregnant Women
2) By Distribution Channel: Hospitals, Pharmacies, Healthcare Providers
3) By End User: Adult, Geriatric, Pediatric
VariZIG Market Trends Influencing Long-Term Demand
In the VariZIG market, key companies are concentrating on technological innovation by scaling up manufacturing and enhancing distribution logistics, such as optimizing contract production, forming regional supply-chain partnerships, and improving cold-chain stability to ensure plasma-derived immunoglobulins reach high-need populations promptly. Manufacturing expansion and distribution logistics involve a collection of process and infrastructure advancements—boosting production capacity, maintaining robust cold-chain and inventory control, creating regional supply agreements, and coordinating procurement contracts—that convert scarce specialty biologics from limited availability into reliable, regionally accessible treatments. For example, in January 2025, Kamada Ltd., an Israel-based biopharmaceutical company specializing in plasma-derived therapies, secured a $25 million three-year contract to deliver KAMRAB and VARIZIG across Latin America from 2025 through 2027. This arrangement secures regional supply and minimizes shortage risks for at-risk patients, allowing hospitals and public health systems to plan prophylaxis and treatment with heightened confidence. It also opens commercial access in a previously fragmented market by generating predictable demand and distribution channels across multiple countries, facilitating quicker patient access. Additionally, the agreement bolsters public-health preparedness for varicella exposure in high-risk groups by ensuring a consistent supply pathway for a vital passive-immunity product.
VariZIG Market Leading Players Shaping Industry Direction
Major companies operating in the varizig market are Emergent BioSolutions Inc.
Access The Complete VariZIG Market Report:
VariZIG Market Largest Region By Revenue And Market Share
North America was the largest region in the varizig market in 2025. The regions covered in the varizig market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model